Abstract: AIM: To study the effects of cyclovirobuxine- D (CVB-D) on experimental arrhythmia and myocardial ischemia.METHODS: The arrhythmia models were set up in the dogs with ligating coronary artery method, and myocardial ischemia model with high-dose pituitrin (0.5 μg·kg ^-1, iv).Some indices were observed, including the influence of CVB-D on the arrhythmia in dogs, acute myocardial ischemia models in rats, and the effects on survival time of hypoxia in mice.Amiodarone (15 mg·kg ^-1, iv) and compound salvia injection (1.0 mg·kg ^-1, iv) were set as controls, respectively, RESULTS: CVB-D could significantly reduce the incidence of ventricular premature beats (VP) and ventricular tachycardia (VT) in dogs, antagonize the rising of STsegment and T-wave of ECG in rats, and lengthen the survival time of hypoxia in mice.CONCLUSION: CVBD (iv) can antagonize arrhythmia and myocardial ischemia in animal models.

Key words: pharmacology, cyclovirobuxine-D, arrhythmia, acute myocardial ischemia, pituitrin